<DOC>
	<DOCNO>NCT02003092</DOCNO>
	<brief_summary>The purpose Phase 1 study determine maximum tolerate dose RX-5902 subject advance metastatic solid tumor .</brief_summary>
	<brief_title>RX-5902 Treatment Subjects With Solid Tumors</brief_title>
	<detailed_description>In dose-finding , open-label , single-agent study RX-5902 , subject treated 6 cycle therapy . RX-5902 administer orally week 3 week follow 1 week rest cycle . All subject follow least 30 day last dose study agent safety .</detailed_description>
	<criteria>Male female 18 yr old Histologically confirm solid tumor malignancy refractory , intolerant , ineligible receive approve standard therapy Measurable evaluable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) Life expectancy least 3 month Able swallow capsule Provide write informed consent Primary brain tumor active brain metastasis Not recover less equal Grade 1 toxicity ( except Grade 2 alopecia neuropathy ) associate previous cancer therapy Any cancer treatment within 2 week plan study treatment History medical psychiatric condition addictive disorder , lab abnormality opinion investigator , may increase risk may interfere study participation interpretation study result History clinically significant GI bleed , intestinal obstruction , GI perforation within 6 month study dose Uncontrolled diabetes History long QT syndrome clinically significant cardiac arrhythmia ( except stable atrial fibrillation ) Myocardial infarction within 6 month study dose Active infection require IV antibiotic within 2 week study dose History Hepatitis B , C , HIV Use potent inhibitor inducer CYP3A4/3A5 within 14 day plan study treatment expect requirement use drug study Use potent inhibitor inducer drug transporter conjugate enzyme within 14 day prior plan study treatment expect requirement use drug study Receiving investigational agent yet complete 30 day since completion investigational study Pregnant , plan pregnancy , breast feed Male female willing use adequate contraceptive precaution study period . Females must either surgically sterile , postmenopausal 12 month , use contraceptive approve sponsor . Unwilling unable provide write informed consent , comply study requirement , available followup assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>Rexahn</keyword>
	<keyword>Phase 1</keyword>
</DOC>